📰 Newspapers

Ebola vaccine trials launches amid security concerns

Ebola vaccine trials launches amid security concerns

Insecurity in eastern DR Congo is likely to make the trial process challenging, warn health experts.

The News

Large-scale trials of three vaccines against the deadly Bundibugyo Ebola strain in the epicenter of DR Congo’s outbreak could yield a breakthrough early next year if security challenges can be overcome, the head of a global vaccine body told Semafor.

The Bundibugyo strain, for which there is no proven vaccine, has killed more than 5,500 people since May’s declaration of an outbreak — now the second-largest ever recorded. Most of the cases, amounting to more than 11,000, have been concentrated in the conflict-hit east of the country.

The Tumaini trial — a study to test vaccine candidates — will see jabs tested on at least 1,000 people to check their safety and efficacy. A trial of Ervebo, a vaccine developed by Merck that has been approved for use against the more common Zaire strain of Ebola, began on Oct. 23. The two other vaccines, which were designed to target the Bundibugyo strain and will join the trial in the next few days, are a jab developed by Oxford University scientists and another by Moderna that harnesses technology used to create vaccines for COVID-19.

“In a best case, we could look towards early next year for a result,” said Richard Hatchett, CEO of the Coalition for Epidemic Preparedness Innovations.

In brief

The News Large-scale trials of three vaccines against the deadly Bundibugyo Ebola strain in the epicenter of DR Congo’s outbreak could yield a breakthrough early next year if security challenges can be overcome, the head of a global vaccine body told Semafor. A trial of Ervebo, a vaccine developed by Merck that has been approved for use against the more common Zaire strain of Ebola, began on Oct.

This is the opening of the story, shared with credit to Semafor. The rest of the report — with every detail — continues on the publisher’s website.

Continue reading at Semafor ↗

Cookie settings

Choose which cookies we may use. You can change this at any time from Cookie settings in the footer. Details of each cookie are in the Cookie Policy.

Strictly necessary

Needed for sign-in, security, payments and remembering these choices. Always on.

Preferences

Remember settings such as dark mode.

Analytics & performance

Help us count visits, understand which pages, devices and countries our readers use, and measure how well the site performs – anonymous and aggregated.

Advertising & marketing

Lets advertising partners show and personalise adverts, measure impressions, clicks and visits, prevent ad fraud and pay us – this is how the free site is funded.

🔔 News notifications

Get headlines from NewsHub on this device — even when the site is closed.

You can switch this off at any time. Works on Android, Windows, Mac and Linux browsers; on iPhone/iPad add the site to your Home Screen first.